C-reactive protein in atherosclerosis: A causal factor?

Cardiovascular Research

Volumn 71, Issue 1, 2006, Pages 30-39

  Paffen, Elaine ^a   deMaat, Moniek P M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Azide; C reactive protein; Inflammation; Thrombosis

Indexed keywords

C REACTIVE PROTEIN; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; LIPID; NITRIC OXIDE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; COMPLEMENT ACTIVATION; DISEASE COURSE; FIBRINOLYSIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LIPID INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

APOPTOSIS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CELL MOVEMENT; COMPLEMENT ACTIVATION; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; LIPID METABOLISM; NITRIC OXIDE; THROMBOSIS;

EID: 33745042652     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.03.004     Document Type: Review

References (111)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
3. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
4. Uhlar C.M., and Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265 (1999) 501-523
5. Black S., Kushner I., and Samols D. C-reactive protein. J Biol Chem 279 (2004) 48487-48490
6. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 (1998) 1477-1482
7. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
8. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
9. Ridker P.M., Buring J.E., Shih J., Matias M., and Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
10. Gill R., Kemp J.A., Sabin C., and Pepys M.B. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 24 (2004) 1214-1218
11. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 Suppl 6A (2004) 9S-16S
12. Pepys M.B., and Hirschfield G.M. C-reactive protein and atherothrombosis. Ital Heart J 2 (2001) 196-199
13. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
14. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
15. Doggen C.J., Berckmans R.J., Sturk A., Manger Cats V., and Rosendaal F.R. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med 248 (2000) 406-414
16. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., and Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
17. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
18. Liu C., Wang S., Deb A., Nath K.A., Katusic Z.S., McConnell J.P., et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res 97 (2005) 135-143
19. Taylor K.E., Giddings J.C., and van den Berg C.W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25 (2005) 1225-1230
20. Bisoendial R.J., Kastelein J.J., Levels J.H., Zwaginga J.J., van den Boogaard B., Reitsma P.H., et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 96 (2005) 714-716
21. Singh U., Devaraj S., and Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25 (2005) 2216-2221
22. Kasper H.U., Schmidt A., and Roessner A. Expression of the adhesion molecules ICAM, VCAM, and ELAM in the arteriosclerotic plaque. Gen Diagn Pathol 141 (1996) 289-294
23. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
24. Libby P., Sukhova G., Lee R.T., and Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 Suppl 2 (1995) S9-S12
25. Seifert P.S., and Hansson G.K. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9 (1989) 802-811
26. Speidl W.S., Exner M., Amighi J., Kastl S.P., Zorn G., Maurer G., et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J (2005) 2294-2299
27. Kassirer M., Zeltser D., Prochorov V., Schoenman G., Frimerman A., Keren G., et al. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 138 (1999) 555-559
28. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
29. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
30. Lombardo A., Biasucci L.M., Lanza G.A., Coli S., Silvestri P., Cianflone D., et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation 109 (2004) 3158-3163
31. Torzewski J., Torzewski M., Bowyer D.E., Frohlich M., Koenig W., Waltenberger J., et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 1386-1392
32. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
33. Tillett W.S., and Francis Jr. T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 52 (1930) 561-585
34. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., and Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12 (1990) 1179-1186
35. Ishikawa T., Imamura T., Hatakeyama K., Date H., Nagoshi T., Kawamoto R., et al. Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation. Am J Cardiol 93 (2004) 611-614
36. Kuta A.E., and Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 164 (1986) 321-326
37. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
38. Shrive A.K., Cheetham G.M., Holden D., Myles D.A., Turnell W.G., Volanakis J.E., et al. Three dimensional structure of human C-reactive protein. Nat Struct Biol 3 (1996) 346-354
39. Verma S., Szmitko P.E., and Yeh E.T. C-reactive protein: structure affects function. Circulation 109 (2004) 1914-1917
40. Diehl E.E., Haines G.K., Radosevich J.A., and Potempa L.A. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319 (2000) 79-83
41. Khreiss T., Jozsef L., Potempa L.A., and Filep J.G. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 (2004) 2016-2022
42. Devaraj S, Venugopal S, Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein, Atherosclerosis; in press, Corrected Proof, Available online 13 May 2005.
43. Schwedler S.B., Amann K., Wernicke K., Krebs A., Nauck M., Wanner C., et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112 (2005) 1016-1023
44. Pepys M.B., Hawkins P.N., Kahan M.C., Tennent G.A., Gallimore J.R., Graham D., et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97 (2005) e97-e103
45. Osterud B. Interaction of endotoxins, blood elements and the vessel wall. Prog Clin Biol Res 189 (1985) 67-79
46. Guha M., and Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 13 (2001) 85-94
47. Rivers R.P., Hathaway W.E., and Weston W.L. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 30 (1975) 311-316
48. Jungi T.W., Miserez R., Brcic M., and Pfister H. Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro. Experientia 50 (1994) 110-114
49. Mackman N. Lipopolysaccharide induction of gene expression in human monocytic cells. Immunol Res 21 (2000) 247-251
50. Nagoshi Y., Kuwasako K., Cao Y.N., Kitamura K., and Eto T. Effects of C-reactive protein on atherogenic mediators and adrenomedullin in human coronary artery endothelial and smooth muscle cells. Biochem Biophys Res Commun 314 (2004) 1057-1063
51. van den Berg C.W., Taylor K.E., and Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 24 (2004) e168-e171
52. Brill A., Yaron G., Dashevsky O., Danenberg H., and Varon D. CRP induces platelet adhesion to endothelial cells under flow. Poster ISTH 2005 Sydney (2005)
53. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
54. Volanakis J.E., and Kaplan M.H. Interaction of C-reactive protein complexes with the complement system: II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 113 (1974) 9-17
55. Szalai A.J., van Ginkel F.W., Wang Y., McGhee J.R., and Volanakis J.E. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol 165 (2000) 1030-1035
56. Giannakis E., Male D.A., Ormsby R.J., Mold C., Jokiranta T.S., Ranganathan S., et al. Multiple ligand binding sites on domain seven of human complement factor H. Int Immunopharmacol 1 (2001) 433-443
57. Szalai A.J., Agrawal A., Greenhough T.J., and Volanakis J.E. C-reactive protein: structural biology and host defense function. Clin Chem Lab Med 37 (1999) 265-270
58. Reynolds G.D., and Vance R.P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 111 (1987) 265-269
59. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
60. Crowell R.E., Du Clos T.W., Montoya G., Heaphy E., and Mold C. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol 147 (1991) 3445-3451
61. Marnell L., Mold C., and Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117 (2005) 104-111
62. Devaraj S., Du Clos T.W., and Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25 (2005) 1359-1363
63. Bharadwaj D., Stein M.P., Volzer M., Mold C., and Du Clos T.W. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 190 (1999) 585-590
64. Escribano-Burgos M., Lopez-Farre A., del Mar G.M., Macaya C., Garcia-Mendez A., Mateos-Caceres P.J., et al. Effect of C-reactive protein on Fcgamma receptor II in cultured bovine endothelial cells. Clin Sci (Lond) 108 (2005) 85-91
65. Nan B., Yang H., Yan S., Lin P.H., Lumsden A.B., Yao Q., et al. C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Surgery 138 (2005) 212-222
66. Penn M.S., and Topol E.J. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 89 (2001) 1-2
67. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 (2001) 1718-1720
68. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063
69. Cushman M., Lemaitre R.N., Kuller L.H., Psaty B.M., Macy E.M., Sharrett A.R., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 19 (1999) 493-498
70. Whisler R.L., Proctor V.K., Downs E.C., and Mortensen R.F. Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP). Lymphokine Res 5 (1986) 223-228
71. Nakagomi A., Freedman S.B., and Geczy C.L. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 101 (2000) 1785-1791
72. Paffen E., Vos H.L., and Bertina R.M. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 24 (2004) 975-981
73. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108 (2003) 512-515
74. Lip G.Y., Blann A.D., Farooqi I.S., Zarifis J., Sagar G., and Beevers D.G. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: the West Birmingham Stroke Project. Blood Coagul Fibrinolysis 13 (2002) 339-347
75. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
76. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
77. Pasceri V., Chang J., Willerson J.T., and Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531-2534
78. Thomassen M.J., Meeker D.P., Deodhar S.D., Wiedemann H.P., and Barna B.P. Activation of human monocytes and alveolar macrophages by a synthetic peptide of C-reactive protein. J Immunother 13 (1993) 1-6
79. Verma S., Badiwala M.V., Weisel R.D., Li S.H., Wang C.H., Fedak P.W., et al. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 126 (2003) 1886-1891
80. Hattori Y., Matsumura M., and Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc. Res. 58 (2003) 186-195
81. Wang C.H., Li S.H., Weisel R.D., Fedak P.W., Dumont A.S., Szmitko P., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
82. Han K.H., Hong K.H., Park J.H., Ko J., Kang D.H., Choi K.J., et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109 (2004) 2566-2571
83. Yamashita H., Shimada K., Seki E., Mokuno H., and Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91 (2003) 133-136
84. Kim S.J., Gershov D., Ma X., Brot N., and Elkon K.B. Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann NY Acad Sci 987 (2003) 68-78
85. Devaraj S., O'keefe G., and Jialal I. Defining the pro-inflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 90 (2005) 4549-4554
86. Ballou S.P., and Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4 (1992) 361-368
87. Devaraj S., Kumaresan P.R., and Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 36 (2004) 405-410
88. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88 (1991) 1121-1127
89. de Lemos J.A., and Morrow D.A. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 4 Suppl 4 (2003) S37-S46
90. Woollard K.J., Philllips D.C., and Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin. Exp. Immunol. 130 (2002) 256-262
91. Schonbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
92. Lin R., Liu J., Gan W., and Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 27 (2004) 1537-1543
93. Varo N., Vicent D., Libby P., Nuzzo R., Calle-Pascual A.L., Bernal M.R., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669
94. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
95. Swafford Jr. A.N., Bratz I.N., Knudson J.D., Rogers P.A., Timmerman J.M., Tune J.D., et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol, Heart Circ Physiol 288 (2005) H1786-H1795
96. Clapp B.R., Hirschfield G.M., Storry C., Gallimore J.R., Stidwill R.P., Singer M., et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111 (2005) 1530-1536
97. Venugopal S.K., Devaraj S., and Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108 (2003) 1676-1678
98. Ikeda U., Takahashi M., and Shimada K. C-reactive protein directly inhibits nitric oxide production by cytokine-stimulated vascular smooth muscle cells. J Cardiovasc Pharmacol 42 (2003) 607-611
99. Lafuente N., Azcutia V., Matesanz N., Cercas E., Rodriguez-Manas L., Sanchez-Ferrer C.F., et al. Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 45 (2005) 193-196
100. Blaschke F., Bruemmer D., Yin F., Takata Y., Wang W., Fishbein M.C., et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 110 (2004) 579-587
101. Gershov D., Kim S., Brot N., and Elkon K.B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
102. Du Clos T.W. Function of C-reactive protein. Ann Med 32 (2000) 274-278
103. Chang M.K., Binder C.J., Torzewski M., and Witztum J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 99 (2002) 13043-13048
104. Klouche M., Gottschling S., Gerl V., Hell W., Husmann M., Dorweiler B., et al. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1376-1385
105. Li L., Roumeliotis N., Sawamura T., and Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95 (2004) 877-883
106. Wadham C., Albanese N., Roberts J., Wang L., Bagley C.J., Gamble J.R., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109 (2004) 2116-2122
107. Pepys M.B. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 25 (2005) 1091-1094
108. Paul A., Ko K.W., Li L., Yechoor V., McCrory M.A., Szalai A.J., et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109 (2004) 647-655
109. *3-Leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1635-1640
110. Reifenberg K., Lehr H.A., Baskal D., Wiese E., Schaefer S.C., Black S., et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?. Arterioscler Thromb Vasc Biol 25 (2005) 1641-1646
111. Ursella S., Mazzone M., Portale G., Testa A., Pignataro G., Covino M., et al. How to use the C-reactive protein in cardiac disease?. Minerva Cardioangiol 53 (2005) 59-68